Literature DB >> 20194846

Accelerated approval and oncology drug development timelines.

Michael L Lanthier, Rajeshwari Sridhara, John R Johnson, Ann Farrell, Patricia Keegan, Robert Justice, Richard Pazdur.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20194846     DOI： 10.1200/JCO.2009.26.2121

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Can cancer clinical trials be fixed?

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2011-01       Impact factor: 54.908

3.  Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.

Authors:  Robert E Martell; David Sermer; Kenneth Getz; Kenneth I Kaitin
Journal:  Oncologist       Date:  2012-12-20

Review 4.  Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.

Authors:  Elena Fountzilas; Rabih Said; Apostolia M Tsimberidou
Journal:  Expert Opin Investig Drugs       Date:  2018-01-22       Impact factor: 6.206
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.